Shares of Intellia Therapeutics (NASDAQ:NTLA) have been given an average rating of “Buy” by the thirteen ratings firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $34.40.
Several research firms have recently weighed in on NTLA. BidaskClub upgraded shares of Intellia Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 13th. JMP Securities began coverage on shares of Intellia Therapeutics in a research note on Thursday, March 8th. They issued an “outperform” rating for the company. Barclays lifted their target price on shares of Intellia Therapeutics from $33.00 to $46.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 7th. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research note on Thursday, March 15th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Intellia Therapeutics in a research note on Wednesday, March 14th.
In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jean Francois Formela sold 39,245 shares of the business’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by insiders.
Shares of NTLA traded up $0.35 during trading hours on Friday, hitting $20.51. The company’s stock had a trading volume of 263,607 shares, compared to its average volume of 1,109,570. The company has a market capitalization of $876.92, a price-to-earnings ratio of -10.82 and a beta of 2.83. Intellia Therapeutics has a 52-week low of $11.15 and a 52-week high of $35.99.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.16). The business had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $8.84 million. Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. Intellia Therapeutics’s revenue for the quarter was up 19.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.31) EPS. research analysts expect that Intellia Therapeutics will post -2.27 earnings per share for the current year.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
